# Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

> **NCT00606632** · PHASE3 · COMPLETED · sponsor: **Heidelberg Pharma AG** · enrollment: 226 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Kidney Cancer

## Interventions

- **DRUG:** 124-Iodine-cG250 (124I-cG250)
- **PROCEDURE:** CT

## Key facts

- **NCT ID:** NCT00606632
- **Lead sponsor:** Heidelberg Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606632, "Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00606632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*